Valeant Profit Rises Amidst Allergan Push

Jul 31 2014 | 11:41am ET

Valeant Pharmaceuticals International turned its second-quarter results announcement into another pitch for its $54 billion offer for rival Allergan Inc.

The Canadian company, which is working with Pershing Square Capital Management on its bid for Allergan, pointed to growth in almost all of its business lines as it announced higher profits and sales. And it said that it remains “focused on completing the Allergan transaction,” in spite of that company’s opposition to it.

Valeant has launched a hostile tender offer for Allergan, while Pershing Square seeks to oust the company’s board. Valeant said it planned to integrate Allergan in much the same way it merged with Bausch & Lomb.

That’s not likely to offer much comfort to Allergan, which has blasted Valeant as a serial acquirer with an unsustainable business strategy.


In Depth

Q&A: Decathlon Capital On Revenue-Based Alternative Lending

Oct 30 2017 | 3:49pm ET

The explosion in private credit activity since the end of the financial crisis is...

Lifestyle

CFA Institute To Add Computer Science To Exam Curriculum

May 24 2017 | 9:25pm ET

Starting in 2019, financial industry executives sitting for the coveted Chartered...

Guest Contributor

CAIS: How Technology is Disrupting the Alternative Investment Industry

Nov 7 2017 | 5:35pm ET

If there’s one thing that alternative investment professionals can agree on, it...